Combat Medical
Combat Medical is a UK medical device company that has developed patented hyperthermic recirculation systems (BRS for HIVEC bladder cancer treatment and PRS+ for HIPEC peritoneal cancer treatment), selling to hospitals across 40+ countries with a 350+ system installed base and pursuing FDA registration for US market entry.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Combat Medical does
Combat Medical Ltd is a UK-based private medical device company that has developed a patented hyperthermic drug delivery platform for treating bladder and peritoneal cancers. The company's core technology consists of two recirculation systems: the Bladder Recirculation System (BRS), which delivers hyperthermic intravesical chemotherapy (HIVEC) by circulating heated mitomycin C inside the bladder at precisely controlled temperatures (43°C) to treat non-muscle invasive bladder cancer (NMIBC); and the PRS+ Peritoneal Recirculation System, which delivers hyperthermic intraperitoneal chemotherapy (HIPEC) with CO2 agitation to support homogeneous drug and heat distribution during cytoreductive surgery for peritoneal malignancies such as locally advanced colorectal cancer. The BRS HIVEC system is positioned as a bladder-preserving alternative to radical cystectomy for BCG-unresponsive high-risk NMIBC patients, with previously reported data showing up to 83% disease-free survival at one year and approximately 80% bladder preservation at two years.
The company generates revenue primarily through hardware sales of its BRS and PRS+ systems to hospitals and cancer treatment centres globally, supported by a distributor network spanning 40+ countries and an installed base of more than 350 HIVEC systems. Over 100,000 HIVEC treatments have been delivered cumulatively, with 2,000+ treatments administered monthly. Go-to-market relies on enterprise field sales to hospital procurement channels, peer-to-peer clinical engagement through an advisory board of leading urologists and surgical oncologists, and conference participation at major events such as the AUA Annual Meeting and EAU Congress. Clinical evidence generation is itself a commercial lever: the HIVEC HEAT Phase 3 trial (238 patients across 25 UK sites, MHRA-approved as an FDA registrational study) and the previously published HIPECT4 Phase 3 trial (in JAMA Surgery and BJS Open, showing 97.6% locoregional control at 3 years versus 87.6% for surgery alone) are central to both regulatory progress and demand generation.
Combat Medical's strategic priorities center on FDA registration and US market entry for HIVEC, supported by a £2.6 million Series A first close in March 2026 led by the T&J Meyer Family Foundation. The company is founder-led (CEO Edward Bruce-White, Founder/Chairman of R&D Alberto Martinez Albalat) and remains in the scale-up phase, with revenue not publicly disclosed but inferred to be in the low-to-mid single-digit millions USD range based on installed base and headcount signals. No AI/ML capabilities are present; the moat is built on patented technology, clinical evidence, regulatory progress, and distributor reach.
Combat Medical firmographics
Firmographics- Name
- Combat Medical
- Legal name
- Combat Medical Ltd
- Website
- https://combatcancer.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Combat Medical is a UK medical device company that has developed patented hyperthermic recirculation systems (BRS for HIVEC bladder cancer treatment and PRS+ for HIPEC peritoneal cancer treatment), selling to hospitals across 40+ countries with a 350+ system installed base and pursuing FDA registration for US market entry.
- Ownership category
- akta.pro rank
Combat Medical industry classification
Industry- Product category
- Hyperthermic Chemotherapy Medical Devices
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Urologic Oncology (HLAKAOAB)
- akta.pro secondary industry
- Surgical Oncology (HLAKAFAG)
Keywords
Where Combat Medical is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Combat Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales (BRS and PRS Systems): Combat Medical sells its proprietary BRS HIVEC and PRS HIPEC recirculation systems to hospitals and cancer treatment centres globally. The installed base of over 350 HIVEC systems across 40+ countries forms the commercial foundation, with future revenue driven by FDA registration enabling US market entry and expanded adoption of both bladder and peritoneal cancer treatment systems.
- Clinical Trial and Regulatory Services: Revenue generated through conducting FDA registrational clinical trials (HIVEC HEAT) that support regulatory approval, with future scale-up operations planned post-approval for US commercial launch.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Combat Medical product offering
Product offeringCore offering
Combat Medical develops, manufactures, and sells two patented hyperthermic chemotherapy recirculation systems: the BRS (Bladder Recirculation System) for hyperthermic intravesical chemotherapy (HIVEC) treatment of non-muscle invasive bladder cancer, and the PRS+ (Peritoneal Recirculation System) for hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery for peritoneal cancers. Both devices heat and recirculate chemotherapy agents within body cavities at precisely controlled temperatures to enhance drug penetration and anti-tumour activity while limiting systemic toxicity.
Product overview
Combat Medical is a medical device company that has developed a patented hyperthermic technology platform comprising two distinct recirculation systems: the Bladder Recirculation System (BRS) for delivering HIVEC (hyperthermic intravesical chemotherapy) to treat bladder cancer, and the PRS+ (Peritoneal Recirculation System) for delivering HIPEC (hyperthermic intraperitoneal chemotherapy) to treat peritoneal cancers. Both systems work by heating and recirculating chemotherapy agents directly at targeted body cavities to enhance drug penetration and efficacy while minimizing systemic toxicity. The company focuses on bladder-sparing and organ-preserving cancer treatments as alternatives to radical surgery.
Differentiator
Problem solved
Functional benefit
Brands
- HIVEC: Hyperthermic intravesical chemotherapy treatment for bladder cancer using the BRS (Bladder Recirculation System)
- HIPEC
- BRS
- PRS+
Products and services
- BRS HIVEC (Bladder Recirculation System) Proprietary bladder recirculation system that delivers hyperthermic intravesical chemotherapy (HIVEC) by circulating heated mitomycin C inside the bladder at precisely controlled temperatures (43°C) via a catheter-based recirculation system. Used in hospitals to treat BCG-unresponsive non-muscle invasive bladder cancer as a bladder-sparing alternative to radical cystectomy.
- PRS+ HIPEC (Peritoneal Recirculation System) Peritoneal recirculation system that delivers hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery, using CO2 agitation to optimize homogeneous drug and thermal distribution throughout the abdominal cavity. Indicated for locally advanced colorectal cancer (pT4), ovarian cancer, and other peritoneal malignancies.
- HIVEC Treatment (Hyperthermic Intravesical Chemotherapy) Hyperthermic intravesical chemotherapy treatment using mitomycin C delivered via the BRS system as a bladder-sparing alternative to radical cystectomy for BCG-unresponsive non-muscle invasive bladder cancer. Marketed to patients and healthcare professionals as the HIVEC treatment protocol enabled by the BRS device.
Quantifiable outcome
- Up to 83% disease-free survival after 1 year in BCG-unresponsive NMIBC patients treated with HIVEC
- +4 more outcomes
Companies that use Combat Medical
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Combat Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Combat Medical partnerships and signals
Strategic signalScale indicators8 records
Recent moves5 records
Expansion highlights5 records
Combat Medical competitors and assessment
Company assessmentDirect peers
- Karl Storz: Karl Storz supplies surgical instrumentation and HIPEC/perfusion systems to surgical oncology departments. Its presence in cytoreductive surgery workflows makes it a direct technology peer to Combat's PRS+ HIPEC offering in the same hospital surgical-oncology channel.
- Merck & Co. Merck's KEYTRUDA (pembrolizumab) is approved for BCG-unresponsive NMIBC and represents the principal systemic-immunotherapy alternative to HIVEC in this patient population. Both companies target the same urology decision-makers and BCG-unresponsive segment.
- ImmunityBio: ImmunityBio's Anktiva (N-803/nogapendekin alfa) is FDA-approved for BCG-unresponsive NMIBC, directly competing with Combat's HIVEC for the same urology prescribing channel and patient population. Both target bladder preservation in BCG-unresponsive disease.
- Cook Medical: Cook Medical manufactures and distributes perfusion and HIPEC delivery systems used in cytoreductive surgery. Combat's PRS+ HIPEC system is a direct competing platform in hyperthermic intraperitoneal chemotherapy for peritoneal and colorectal cancer.
Emerging players
- Theralase Technologies: Theralase is developing a photosensitiser-based intravesical therapy for BCG-unresponsive NMIBC. While its mechanism is distinct, it targets the same bladder-preservation indication and BCG-unresponsive patient segment as Combat's HIVEC.
- CG Oncology: CG Oncology is developing cretostimogene grenadenorepvec, a gene therapy for BCG-unresponsive NMIBC in late-stage trials. It targets the same bladder-preservation opportunity that Combat's HIVEC addresses, representing a likely future competitor in the same NMIBC niche.
- enGene: enGene is developing EG-70, a gene therapy for BCG-unresponsive NMIBC, positioning it as a future bladder-sparing alternative to HIVEC in the same urology prescribing channel and BCG-unresponsive patient segment.
- Photocure: Photocure commercialises Hexvix/Cysview, a bladder cancer detection agent used in urology departments. While not a therapeutic competitor, Photocure operates in the same hospital urology workflow and addresses the same bladder cancer patient pool, making it an adjacent category peer.
Broad incumbents
- Ferring Pharmaceuticals: Ferring is the principal global supplier of BCG (TICE/OncoTICE) for NMIBC. Its installed position as the standard-of-care intravesical therapy defines the addressable BCG-unresponsive pool that Combat's HIVEC depends on, making it the dominant contextual incumbent in this disease.
- Becton, Dickinson and Company: BD is a broad incumbent in urology devices, including bladder cancer management instrumentation and consumables. While not a direct hyperthermic chemotherapy competitor, BD operates in the same hospital urology supply channel and competes for the same hospital procurement budget.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Combat Medical social profiles
Digital presenceCombat Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Combat Medical leadership team
Management profileNumber of profiles
Profiles4 records
Combat Medical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Combat Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Combat Medical
What does Combat Medical do?
Combat Medical develops, manufactures, and sells two patented hyperthermic chemotherapy recirculation systems: the BRS (Bladder Recirculation System) for hyperthermic intravesical chemotherapy (HIVEC) treatment of non-muscle invasive bladder cancer, and the PRS+ (Peritoneal Recirculation System) for hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery for peritoneal cancers. Both devices heat and recirculate chemotherapy agents within body cavities at precisely controlled temperatures to enhance drug penetration and anti-tumour activity while limiting systemic toxicity.
Is Combat Medical a public or private company?
Combat Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Combat Medical founded?
Combat Medical was founded in 2011. It employs 11 to 50 people.
Where is Combat Medical based?
Combat Medical is headquartered in London, United Kingdom, in the Europe region.
How does Combat Medical make money?
Two revenue lines are on record. Medical Device Sales (BRS and PRS Systems) is the primary driver. The others are clinical Trial and Regulatory Services.
Who are Combat Medical's main competitors?
Direct peers on record are Karl Storz, Merck & Co., ImmunityBio and Cook Medical. Emerging players are Theralase Technologies, CG Oncology, enGene and Photocure. Broad incumbents are Ferring Pharmaceuticals and Becton, Dickinson and Company.
Does Combat Medical have an API?
No public API is recorded for Combat Medical.
What industry is Combat Medical in?
Combat Medical's product category is Hyperthermic Chemotherapy Medical Devices. Its primary akta.pro industry code is HLAKAOAB, Urologic Oncology, with a secondary code of HLAKAFAG, Surgical Oncology. Its SIC code is 3841.